TTI-621 is under clinical development by Pfizer and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TTI-621’s likelihood of approval (LoA) and phase transition for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) took place on 22 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TTI-621 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TTI-621 overview

TTI-621 (SIRPa Fc) is under development for treatment of relapsed or refractory lymphomas, solid tumors like indolent B-cell lymphoma, aggressive B-cell lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia, relapsed or refractory multiple myeloma, acute myeloid leukemia, small-cell lung cancer, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, diffuse large B-cell lymphoma, leiomyosarcoma, soft-tissue sarcomas including high-grade leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, angiosarcoma, follicular lymphoma, primary mediastinal (thymic) large B-cell lymphoma and epithelioid sarcoma. It is administered through intratumoral and intravenous route. SIRPaFc (TTI-621) is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). The drug candidate targets CD47. It was also under development for the treatment of mycosis fungoides, Sezary syndrome, melanoma (intratumoral).

Pfizer overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

Quick View TTI-621 LOA Data

Report Segments
  • Innovator
Drug Name
  • TTI-621
Administration Pathway
  • Intratumor
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Pfizer
  • Originator: University Health Network and Hospital for Sick Children
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.